Partner with Trevi Therapeutics

We are actively seeking ex-US commercial partners who share our dedication to helping improve the quality of life of patients.

We currently have clinical trials for our investigational therapy Haduvio™ (nalbuphine ER) in pruritus associated with prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis. We are also exploring future clinical trials in other dermatologic and respiratory indications, as well other neurologically mediated diseases such as Levodopa Induced Dyskinesia.

for partnering enquiries

Ways to Collaborate

Out-Licensing

We are looking to grow our ex-US partnerships for Haduvio™, an investigational oral extended-release therapy with a unique dual-acting mechanism of action (MOA).

Haduvio Overview:

  •  18 issued US and foreign patents with terms expiring from 2026 to 2032 and additional applications with terms, if issued, expiring from 2032 to 2041.
  • Only oral dual acting MOA in clinical development that works both peripherally and centrally to rebalance the kappa and mu receptors.

Learn more about Haduvio.